Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 3,279 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Withdrawn Phase 3 Interventional

A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Heart Surgery

NCT00464763
View directory record Official record
Conditions
Delirium
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
11
States / cities
Loma Linda, California • Towson, Maryland • Grand Blanc, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 30, 2026, 10:32 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

NCT05156398
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
56
States / cities
Fort Smith, Arkansas • Hawthorne, California • La Mesa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

NCT01302119
View directory record Official record
Conditions
Onychomycosis of Toenails
Interventions
AN2690 Topical Solution, 5%, Solution Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Novato, California • Oceanside, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Circadian Rhythms of Aqueous Humor Dynamics in Humans

NCT00572936
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Dorzolamide, Timolol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

NCT01257230
View directory record Official record
Conditions
Asthma
Interventions
tiotropium Respimat low dose, placebo Respimat, tiotropium Respimat high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Plymouth, Minnesota • Columbia, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated Phase 3 Interventional Results available

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

NCT00138671
View directory record Official record
Conditions
Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
Interventions
Subcutaneous Insulin, Inhaled Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 77 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
77
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Oct 30, 2026, 10:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Instrumented Data Exchange for Ataxia Study

NCT04268147
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Friedreich Ataxia
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
12 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated Phase 3 Interventional Results available

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

NCT00585312
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
23
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 4 Interventional Results available

Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

NCT00129961
View directory record Official record
Conditions
Skin Neoplasms, Kidney Transplantation
Interventions
sirolimus, cyclosporine or tacrolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

NCT02118792
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2%, Matching vehicle control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Henrico, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients

NCT00643734
View directory record Official record
Conditions
Pneumonia
Interventions
azithromycin sustained release, placebo, levofloxacin
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
35
States / cities
Mesa, Arizona • Phoenix, Arizona • San Luis Obispo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2008 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

NCT05543616
View directory record Official record
Conditions
SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Interventions
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 11 Years
Enrollment
4,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

NCT02637193
View directory record Official record
Conditions
Healthy Subjects
Interventions
Venlafaxine, Moxifloxacin, Drug - placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated No phase listed Observational

Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

NCT01532232
View directory record Official record
Conditions
Breast Cancer, Tobacco Dependence
Interventions
placebo, varenicline
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

NCT00117598
View directory record Official record
Conditions
Lymphoma
Interventions
Temsirolimus (CCI-779), Investigator's choice
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Little Rock, Arkansas • Fountain Valley, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers

NCT00392080
View directory record Official record
Conditions
Osteoarthritis
Interventions
CJ-023,423, placebo, naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
11
States / cities
Anaheim, California • San Diego, California • Jupiter, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated Phase 2 Interventional

For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy

NCT00037180
View directory record Official record
Conditions
Neoplasm Metastasis, Colorectal Neoplasms
Interventions
Celecoxib, Irinotecan, 5-fluorouracil, Leucovorin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
12
States / cities
Mobile, Alabama • Fort Lauderdale, Florida • Port Saint Lucie, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated Phase 2 Interventional Results available

A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

NCT00999518
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
Tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
122
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated Phase 1 Interventional Results available

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

NCT02122146
View directory record Official record
Conditions
Neoplasms
Interventions
PF-06664178
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

NCT02871037
View directory record Official record
Conditions
Normal Healthy
Interventions
PF-05221304, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated Phase 1 Interventional

Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus

NCT00479622
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
TRU-015
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 8, 2008 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Early Phase 1 Interventional

Fetal Hemoglobin Induction Treatment Metformin

NCT02981329
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell Disease, Hemoglobin Disorder
Interventions
Metformin, Questionnaires
Drug · Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated Phase 1 Interventional Results available

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

NCT01347866
View directory record Official record
Conditions
Advanced Cancer
Interventions
PF-05212384, PD-0325901, irinotecan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Fesoterodine "add-on" Male Overactive Bladder Study

NCT00546637
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older · Male only
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2011 · Synced Oct 30, 2026, 10:32 PM EDT